Medytox Competitors and Similar CompaniesClear all
Genentech's competitors and similar companies include Ipsen, CSL Behring and Biogen.
 Genentech Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines. |  Biogen Biogen (formerly known as Biogen Idec) is a biopharmaceutical company that develops and delivers therapies for neurological and neurodegenerative diseases. | |||
Founding Date | Founding Date 1976 | Founding Date 1929 | Founding Date 1904 | Founding Date 1978 |
Type | Type Subsidiary | Type Public | Type Subsidiary | Type Public |
Tags | ||||
Locations | Locations South San Francisco, US HQ Hillsboro, US Oceanside, US Portland, US South San Francisco, US South San Francisco, US South San Francisco, US see more | Locations Boulogne-Billancourt, FR HQ Algiers, DZ South Yarra, AU Wien, AT Merelbeke, BE São Paulo, BR Mississauga, CA see more | Locations King of Prussia, US HQ Broadmeadows, AU Parkville, AU Parkville, AU Wien, AT Mechelen, BE see more | Locations Cambridge, US HQ Vicente López, AR Macquarie Park, AU Wien, AT Machelen, BE São Paul, BR Toronto, CA see more |
Employees | Employees 18,077 | Employees 5,358 | Employees 7,5692% decrease | Employees 7,605 |
Valuation ($) | Valuation ($) N/A | Valuation ($) 10.2 b | Valuation ($) N/A | Valuation ($) 26.7 b |
Financial | ||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) €3.7b (FY, 2025) | Revenue (est.) $7.9b (FY, 2020) | Revenue (est.) $9.9b (FY, 2025) |
Cost of goods | Cost of goods N/A | Cost of goods €659.1m (FY, 2025) | Cost of goods N/A | Cost of goods $2.4b (FY, 2025) |
Gross profit | Gross profit N/A | Gross profit €3.3b (FY, 2025) | Gross profit $4.5b (FY, 2020) | Gross profit $7.5b (FY, 2025) |
Net income | Net income N/A | Net income €445.1m (FY, 2025) | Net income N/A | Net income $1.3b (FY, 2025) |
Operating ⚠ | ||||
Phase I Trials Products | Phase I Trials Products 28 (Jul, 2025) | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products 4 (FY, 2024) |
Phase II Trials Products | Phase II Trials Products 19 (Jul, 2025) | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products 6 (FY, 2024) |
Phase III Trials Products | Phase III Trials Products 41 (Jul, 2025) | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products 11 (FY, 2024) |
For sources of this data, please see the company profile
View Company Profiles
Biogen
HQ
Cambridge, US
Employees
7,605
Biogen (formerly known as Biogen Idec) is a biopharmaceutical company that develops and delivers therapies for neurological and neurodegenerative diseases.
View company